Knott David M Jr Purchases 6,000 Shares of Johnson & Johnson $JNJ

Knott David M Jr raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 650.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,922 shares of the company’s stock after acquiring an additional 6,000 shares during the quarter. Knott David M Jr’s holdings in Johnson & Johnson were worth $1,057,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter valued at approximately $35,000. Stone House Investment Management LLC bought a new stake in Johnson & Johnson in the first quarter valued at $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $48,000. Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson in the 1st quarter valued at $52,000. Finally, Pandora Wealth Inc. acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth about $65,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 0.4%

NYSE:JNJ opened at $196.00 on Monday. Johnson & Johnson has a one year low of $140.68 and a one year high of $197.18. The firm has a market capitalization of $472.22 billion, a price-to-earnings ratio of 18.92, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The business has a fifty day moving average price of $185.81 and a 200-day moving average price of $170.14. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Stifel Nicolaus boosted their target price on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research note on Wednesday, October 15th. Citigroup increased their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 15th. JPMorgan Chase & Co. boosted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Finally, Argus set a $210.00 price target on Johnson & Johnson in a research note on Wednesday, October 15th. Four research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $201.05.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.